Literature DB >> 16229906

Acute and chronic effects of relaxin on vasoactivity, myogenic reactivity and compliance of the rat mesenteric arterial and venous vasculature.

Yang Li1, Zoë L S Brookes, Susan Kaufman.   

Abstract

We investigated the effect of relaxin on vasodilation, myogenic reactivity, and compliance of small mesenteric arteries and veins. In acute experiments, small (second order) mesenteric arteries and veins from female rats were mounted in a pressure myograph, perfused intraluminally with relaxin, and exposed to incremental increases in intraluminal pressure (20-120 mm Hg for arteries, 2-12 mm Hg for veins). We expressed myogenic reactivity as the ratio of active to passive diameter at each pressure step. In chronic experiments, relaxin was administered to rats (4 microg/h) for 3 days prior to isolating the vessels and measuring myogenic reactivity. Arteries were more sensitive than were veins to the acute vasodilatory activity of relaxin (EC50: arteries=1.32+/-0.18x10(-8) M; veins=3.19+/-0.88x10(-8) M, P<0.05). Acute relaxin reduced myogenic reactivity of mesenteric arteries, but not veins. Chronic pretreatment with relaxin did alter the pressure/diameter relationship in Ca(2+)-containing medium, but this was due to increased passive compliance (control: 2.96+/-0.14 microm mm Hg(-1), n=5; relaxin: 3.72+/-0.16 microm mm Hg(-1), n=5) rather than to reduced myogenic reactivity. Chronic relaxin did not alter myogenic reactivity or compliance (control: 43.8+/-1.4 microm mm Hg(-1), n=5; relaxin: 46.1+/-2.3 microm mm Hg(-1), n=5) of veins. Thus, although relaxin reduces total peripheral resistance, it does not affect splanchnic venous capacitance or tone. In the face of elevated plasma relaxin levels, such as during pregnancy, cardiac preload may thus be maintained, concurrent with a reduction in cardiac afterload and blood pressure. We caution that, if an experimental treatment alters compliance, myogenic reactivity must be expressed as the ratio of active:passive diameter.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16229906     DOI: 10.1016/j.regpep.2005.09.009

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  12 in total

Review 1.  Vascular actions of relaxin: nitric oxide and beyond.

Authors:  C H Leo; M Jelinic; H H Ng; S A Marshall; J Novak; M Tare; K P Conrad; L J Parry
Journal:  Br J Pharmacol       Date:  2016-09-30       Impact factor: 8.739

2.  Differential effects of relaxin deficiency on vascular aging in arteries of male mice.

Authors:  Maria Jelinic; Marianne Tare; Kirk P Conrad; Laura J Parry
Journal:  Age (Dordr)       Date:  2015-06-25

3.  Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferator-activated receptor-γ.

Authors:  Siu-Lung Chan; Marilyn J Cipolla
Journal:  FASEB J       Date:  2011-05-20       Impact factor: 5.191

Review 4.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

5.  Relaxin peptide hormones are protective during the early stages of ischemic stroke in male rats.

Authors:  Lindsay H Bergeron; Jordan M Willcox; Faisal J Alibhai; Barry J Connell; Tarek M Saleh; Brian C Wilson; Alastair J S Summerlee
Journal:  Endocrinology       Date:  2014-12-02       Impact factor: 4.736

6.  Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteins.

Authors:  M Sarwar; C S Samuel; R A Bathgate; D R Stewart; R J Summers
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

Review 7.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 8.  Emerging role of serelaxin in the therapeutic armamentarium for heart failure.

Authors:  Brandon C Varr; Mathew S Maurer
Journal:  Curr Atheroscler Rep       Date:  2014-10       Impact factor: 5.113

9.  Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment.

Authors:  Maria Jelinic; Chen-Huei Leo; Emiel D Post Uiterweer; Shaun L Sandow; Jonathan H Gooi; Mary E Wlodek; Kirk P Conrad; Helena Parkington; Marianne Tare; Laura J Parry
Journal:  FASEB J       Date:  2013-09-13       Impact factor: 5.191

10.  Time-dependent activation of prostacyclin and nitric oxide pathways during continuous i.v. infusion of serelaxin (recombinant human H2 relaxin).

Authors:  C H Leo; M Jelinic; H H Ng; M Tare; L J Parry
Journal:  Br J Pharmacol       Date:  2016-02-17       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.